JP2009502963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502963A5 JP2009502963A5 JP2008524227A JP2008524227A JP2009502963A5 JP 2009502963 A5 JP2009502963 A5 JP 2009502963A5 JP 2008524227 A JP2008524227 A JP 2008524227A JP 2008524227 A JP2008524227 A JP 2008524227A JP 2009502963 A5 JP2009502963 A5 JP 2009502963A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- compound
- deuterium
- salt
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrugs Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 229910052805 deuterium Inorganic materials 0.000 claims 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 206010057840 Major depression Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 2
- -1 or a hydrate Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 206010007541 Cardiac disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010013954 Dysphoria Diseases 0.000 claims 1
- 206010018075 Generalised anxiety disease Diseases 0.000 claims 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033666 Panic disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010036596 Premature ejaculation Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000002996 emotional Effects 0.000 claims 1
- 201000006529 generalized anxiety disease Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 230000003340 mental Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 1
- 201000001552 phobic disease Diseases 0.000 claims 1
- 200000000002 platelet activation Diseases 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000000391 smoking Effects 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
Claims (10)
- Y2及びY3の両方が独立に重水素である、請求項1に記載の化合物。
- 前記化合物の塩又はそのプロドラッグの塩が薬学上許容可能な塩である、請求項1〜3のいずれか1項に記載の化合物又はプロドラッグ。
- 有効量の請求項1に記載の式Iの化合物、又は薬学上許容可能なその塩、プロドラッグ、又は薬学上許容可能な前記プロドラッグの塩、又はその水和物、溶媒和物又は多形体、及び許容可能なキャリアを含む組成物。
- うつ病、強迫強制障害、全般性不安障害、外傷後ストレス、大うつ病、パニック障害、対人恐怖症、月経前症候群、心臓障害、非心臓性胸痛、禁煙又は再喫煙の防止である喫煙中毒、血小板活性化の低下状態、アルコール中毒症及びアルコール依存症、憤怒、拒絶、感受性及び精神又は身体のエネルギーの欠如を含む精神医学症候群、後期黄体期不機嫌症、早漏、老人性認知症、肥満、パーキンソン病、イヌの感情的攻撃、癌細胞の増殖、骨粗しょう症、増殖性の又は炎症性の皮膚疾患のような皮膚の疾患又は障害の治療、又は早すぎる女性のオーガズムの治療に用いられる、請求項5に記載の組成物。
- うつ病の緩和又は予防に用いられる、請求項6に記載の組成物。
- 大うつ病の緩和又は予防に用いられる、請求項6に記載の組成物。
- 水素原子すべてが天然の同位元素の存在率で存在する、請求項9に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70407305P | 2005-07-29 | 2005-07-29 | |
US60/704,073 | 2005-07-29 | ||
PCT/US2006/029599 WO2007016431A2 (en) | 2005-07-29 | 2006-07-28 | Novel benzo [d] [1,3]-dioxol derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009502963A JP2009502963A (ja) | 2009-01-29 |
JP2009502963A5 true JP2009502963A5 (ja) | 2009-09-17 |
JP5301991B2 JP5301991B2 (ja) | 2013-09-25 |
Family
ID=37709249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008524227A Expired - Fee Related JP5301991B2 (ja) | 2005-07-29 | 2006-07-28 | 新規なベンゾ[d][1,3]−ジオキソール誘導体 |
Country Status (13)
Country | Link |
---|---|
US (5) | US20080287495A1 (ja) |
EP (1) | EP1910322B1 (ja) |
JP (1) | JP5301991B2 (ja) |
KR (1) | KR101380190B1 (ja) |
CN (1) | CN101273024A (ja) |
AU (1) | AU2006275595B2 (ja) |
BR (1) | BRPI0615973A2 (ja) |
CA (1) | CA2616383C (ja) |
EA (1) | EA014432B1 (ja) |
ES (1) | ES2396365T3 (ja) |
HK (1) | HK1117532A1 (ja) |
WO (1) | WO2007016431A2 (ja) |
ZA (1) | ZA200800785B (ja) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006275595B2 (en) * | 2005-07-29 | 2012-08-16 | Concert Pharmaceuticals Inc. | Novel benzo [d] [1,3]-dioxol derivatives |
US20070112031A1 (en) * | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
WO2007113155A1 (en) * | 2006-04-03 | 2007-10-11 | F. Hoffmann-La Roche Ag | Process for preparation of enantiomerically enriched cyclic β-aryl or heteroaryl carboxylic acids |
EP2099299A4 (en) * | 2006-10-23 | 2011-11-30 | Concert Pharmaceuticals Inc | OXAZOLIDINONE DERIVATIVES AND METHOD FOR THEIR USE |
EP2139877B1 (en) * | 2007-03-07 | 2011-05-11 | Concert Pharmaceuticals Inc. | Deuterated piperazine derivatives as anti-anginal compounds |
EP2152709B1 (en) * | 2007-05-01 | 2012-02-22 | Concert Pharmaceuticals Inc. | Morphinan compounds |
JP4642134B2 (ja) * | 2007-05-01 | 2011-03-02 | コンサート ファーマシューティカルズ インコーポレイテッド | ナフチル(エチル)アセトアミド |
ES2577477T3 (es) | 2007-05-01 | 2016-07-15 | Concert Pharmaceuticals Inc. | Compuestos morfinanos |
AU2008266124A1 (en) * | 2007-06-13 | 2008-12-24 | Auspex Pharmaceuticals, Inc. | Substituted piperazines |
EP2727915B1 (en) | 2007-09-13 | 2016-04-13 | Concert Pharmaceuticals Inc. | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof |
WO2010009243A1 (en) * | 2008-07-15 | 2010-01-21 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
WO2010010141A1 (en) * | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Pramipexole for treating cardiomyopathy |
US20100093721A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
US9045453B2 (en) | 2008-11-14 | 2015-06-02 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
ES2444433T3 (es) * | 2008-11-14 | 2014-02-25 | Concert Pharmaceuticals, Inc. | Derivados de dioxopiperidinil-ftalimida sustituidos |
WO2010077730A2 (en) * | 2008-12-09 | 2010-07-08 | Auspex Pharmaceutical, Inc | Indanone inhibitors of acetylcholinesterase |
WO2010075086A2 (en) * | 2008-12-15 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Pyrrolidinone inhibitors of pde-4 |
US8940727B2 (en) * | 2009-10-26 | 2015-01-27 | Otsuka Pharmaceutical Co., Ltd. | Benzazepine compound |
WO2011159920A1 (en) * | 2010-06-17 | 2011-12-22 | Concert Pharmaceuticals, Inc. | [5,6]-dihydro-2h-pyran-2-one derivatives |
US8575174B2 (en) | 2011-06-20 | 2013-11-05 | H. Lundbeck A/S | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia |
KR101950057B1 (ko) * | 2012-01-31 | 2019-02-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 파록세틴 유도체 |
WO2013116480A1 (en) | 2012-02-03 | 2013-08-08 | Selectx Pharmaceuticals, Inc. | 4,6-substituted 2,5-dideoxystreptamine aminoglycoside antibiotics |
EP2687854A1 (en) * | 2012-07-19 | 2014-01-22 | Chiron AS | Test kit for the quantitative determination of narcotic drugs |
US9643950B2 (en) | 2012-10-22 | 2017-05-09 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
AR094054A1 (es) * | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
EP2970206A1 (en) | 2013-03-13 | 2016-01-20 | Boston Biomedical, Inc. | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
RS59018B1 (sr) * | 2013-06-27 | 2019-08-30 | Pfizer | Heteroaromatična jedinjenja i njihova upotreba kao dopamin d1 liganada |
CN104059030B (zh) | 2014-05-30 | 2016-05-04 | 镇江圣安医药有限公司 | [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途 |
CA2945609C (en) | 2014-07-29 | 2023-05-23 | Shenzhen Hightide Biopharmaceutical, Ltd. | Berberine-ursodeoxycholic salt, method of preparation and application therof |
US10037449B1 (en) | 2015-09-29 | 2018-07-31 | Amazon Technologies, Inc. | Inventory tracking using RFID |
US10089505B1 (en) | 2015-09-29 | 2018-10-02 | Amazon Technologies, Inc. | Inventory tracking using RFID |
DK3452465T3 (da) | 2016-05-04 | 2021-02-08 | Genoscience Pharma | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |
AU2016406709C1 (en) | 2016-05-10 | 2023-04-27 | Shenzhen Hightide Biopharmaceutical., Ltd. | Composition, and application and pharmaceutical preparation thereof |
AU2017376922B2 (en) | 2016-12-15 | 2022-12-01 | Société des Produits Nestlé S.A. | Compositions and methods that modulate phosphorus or enzymes in a companion animal |
CN108864077B (zh) | 2017-05-12 | 2020-05-22 | 深圳君圣泰生物技术有限公司 | 小檗碱有机酸盐的固体形式及其制备方法 |
CN109134432B (zh) * | 2017-06-15 | 2021-06-11 | 北京君科华元医药科技有限公司 | 氘代抗抑郁药物 |
EP3675860B1 (en) | 2017-08-28 | 2023-03-08 | Zhihong, Chen | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof |
CN107970243B (zh) * | 2017-10-30 | 2020-07-28 | 江苏理工学院 | 一种去甲氯氮平的新用途 |
JP2022506908A (ja) | 2018-11-01 | 2022-01-17 | リンク・ファーマシューティカルズ・カンパニー・リミテッド | 三環系ヤヌスキナーゼ1阻害剤ならびにその組成物および方法 |
US11535600B2 (en) | 2018-12-03 | 2022-12-27 | H. Lundbeck A/S | Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine |
WO2020146845A1 (en) | 2019-01-11 | 2020-07-16 | University Of Rochester | Compositions and methods for treating prostate cancer with enzalutamide and an inhibitor of monoamin oxidase a |
KR20210141461A (ko) | 2019-02-01 | 2021-11-23 | 캔웰 바이오테크 리미티드 | 이미다조퀴놀린 아민 유도체, 약제학적 조성물, 이의 용도 |
US10906923B1 (en) | 2019-02-07 | 2021-02-02 | Canwell Biotech Limited | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof |
CN110283156B (zh) * | 2019-07-29 | 2020-06-30 | 河北省农林科学院经济作物研究所 | 从刺五加中提取的新型降血脂化合物 |
JP2022550851A (ja) | 2019-10-04 | 2022-12-05 | シージェン インコーポレイテッド | カンプトテシンペプチドコンジュゲート |
EP4138840A1 (en) | 2020-04-22 | 2023-03-01 | University of Rochester | Compositions and methods for treating metabolic and cardiovascular diseases |
AU2022297453A1 (en) | 2021-06-22 | 2024-01-04 | Crimson Biopharm Inc. | (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
US5167948A (en) * | 1987-08-07 | 1992-12-01 | Mallinckrodt Medical, Inc. | Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound |
US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
WO1995026325A2 (en) * | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
PT994872E (pt) * | 1997-06-10 | 2001-09-28 | Synthon Bv | Composto de 4-fenilpiperidina |
US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
EP1134290A3 (en) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
US6436938B1 (en) * | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
US6720003B2 (en) * | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
AU2006275595B2 (en) * | 2005-07-29 | 2012-08-16 | Concert Pharmaceuticals Inc. | Novel benzo [d] [1,3]-dioxol derivatives |
US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
US7598273B2 (en) * | 2005-10-06 | 2009-10-06 | Auspex Pharmaceuticals, Inc | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties |
US20070112031A1 (en) * | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
US20080103122A1 (en) * | 2006-09-05 | 2008-05-01 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
EP2727915B1 (en) * | 2007-09-13 | 2016-04-13 | Concert Pharmaceuticals Inc. | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof |
-
2006
- 2006-07-28 AU AU2006275595A patent/AU2006275595B2/en not_active Ceased
- 2006-07-28 CA CA2616383A patent/CA2616383C/en active Active
- 2006-07-28 EP EP06813250A patent/EP1910322B1/en active Active
- 2006-07-28 CN CNA2006800351923A patent/CN101273024A/zh active Pending
- 2006-07-28 ES ES06813250T patent/ES2396365T3/es active Active
- 2006-07-28 BR BRPI0615973-7A patent/BRPI0615973A2/pt not_active IP Right Cessation
- 2006-07-28 EA EA200800490A patent/EA014432B1/ru not_active IP Right Cessation
- 2006-07-28 KR KR1020087004867A patent/KR101380190B1/ko not_active IP Right Cessation
- 2006-07-28 JP JP2008524227A patent/JP5301991B2/ja not_active Expired - Fee Related
- 2006-07-28 WO PCT/US2006/029599 patent/WO2007016431A2/en active Application Filing
- 2006-07-31 US US11/498,334 patent/US20080287495A1/en not_active Abandoned
-
2007
- 2007-02-08 US US11/704,554 patent/US7678914B2/en not_active Expired - Fee Related
-
2008
- 2008-01-25 ZA ZA200800785A patent/ZA200800785B/xx unknown
- 2008-10-16 HK HK08111437.0A patent/HK1117532A1/xx not_active IP Right Cessation
-
2010
- 2010-01-15 US US12/688,466 patent/US8450492B2/en not_active Expired - Fee Related
-
2013
- 2013-05-24 US US13/901,651 patent/US20140018390A1/en not_active Abandoned
-
2015
- 2015-03-10 US US14/644,012 patent/US20150196544A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009502963A5 (ja) | ||
KR101098480B1 (ko) | 3치환2(아릴알킬)1아자바이시클로알칸 및 그 사용방법 | |
CN103249697B (zh) | 适用作多巴胺能稳定剂的普利多匹定(pridopidine)氘化类似物 | |
JP6047556B2 (ja) | Lrrk2キナーゼ活性の阻害剤 | |
JP2009514782A (ja) | グリコーゲン合成酵素キナーゼ3阻害剤としてのトリアゾロピリミジン誘導体 | |
JP2009502961A5 (ja) | ||
RU2018130727A (ru) | Органические соединения | |
JP2008524262A5 (ja) | ||
JP2003511434A (ja) | モノアミン再取込み阻害剤として有用な新規ビアリールエーテル誘導体 | |
JP2009536161A5 (ja) | ||
TW200724541A (en) | Imidazoquinolines as lipid kinase inhibitors | |
HUE030048T2 (hu) | Új VI kristályos formájú agomelatin, elõállításának módszere és abból készült gyógyszerészeti készítmények | |
JP2012528105A5 (ja) | ||
AU2016324495B2 (en) | Carborane compounds and methods of use thereof | |
TWI633104B (zh) | 6,7,8,9-四氫-5H-吡啶并[2,3-d]氮呯多巴胺D3配體 | |
JP2007520539A5 (ja) | ||
JP2015502371A5 (ja) | ||
TW200806636A (en) | Glycine transporter-1 inhibitors | |
TW200413367A (en) | Novel processes and intermediates for preparing triazolo-pyridines | |
JP2010540470A5 (ja) | ||
JP2007523207A5 (ja) | ||
JPS63502825A (ja) | 経口活性非耽溺性鎮痛剤 | |
AU2019393785A2 (en) | Carborane compounds, carborane analogs, and methods of use thereof | |
JP2007506726A5 (ja) | ||
CN109134432B (zh) | 氘代抗抑郁药物 |